MolYsis-SN plus™ IVD

About Molzym

Founded in 2004 and based in Bremen, Germany, Molzym has established itself as a leader in molecular solutions for direct pathogen detection. Its proprietary MolYsis™ technology addresses a key bottleneck in molecular diagnostics by removing host DNA, thereby significantly improving the sensitivity of PCR and NGS-based methods for identifying bacteria and fungi. The company offers a portfolio of IVD kits and research-use-only reagents, serving both clinical diagnostics and life science research markets. In a significant recent development, Molzym has been acquired by Bruker Corporation, marking a new phase in its growth and technology integration.

Therapeutic Areas